Literature DB >> 16138106

Opportunities and challenges in antiparasitic drug discovery.

Richard Pink1, Alan Hudson, Marie-Annick Mouriès, Mary Bendig.   

Abstract

New antiparasitic drugs are urgently needed to treat and control diseases such as malaria, leishmaniasis, sleeping sickness and filariasis, which affect millions of people each year. However, because the majority of those infected live in countries in which the prospects of any financial return on investment are too low to support market-driven drug discovery and development, alternative approaches are needed. In this article, challenges and opportunities for antiparasitic drug discovery are considered, highlighting some of the progress that has been made in recent years, partly through scientific advances, but also by more effective partnership between the public and private sectors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138106     DOI: 10.1038/nrd1824

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  102 in total

Review 1.  Global phenotypic screening for antimalarials.

Authors:  W Armand Guiguemde; Anang A Shelat; Jose F Garcia-Bustos; Thierry T Diagana; Francisco-Javier Gamo; R Kiplin Guy
Journal:  Chem Biol       Date:  2012-01-27

Review 2.  Target assessment for antiparasitic drug discovery.

Authors:  Julie A Frearson; Paul G Wyatt; Ian H Gilbert; Alan H Fairlamb
Journal:  Trends Parasitol       Date:  2007-10-24

3.  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

Authors:  Ramesh Gujjar; Alka Marwaha; Farah El Mazouni; John White; Karen L White; Sharon Creason; David M Shackleford; Jeffrey Baldwin; William N Charman; Frederick S Buckner; Susan Charman; Pradipsinh K Rathod; Margaret A Phillips
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

4.  New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.

Authors:  Ranjan Behera; Sarah M Thomas; Kojo Mensa-Wilmot
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

5.  First small molecular inhibitors of T. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness.

Authors:  Terry K Smith; Benjamin L Young; Helen Denton; David L Hughes; Gerd K Wagner
Journal:  Bioorg Med Chem Lett       Date:  2009-01-30       Impact factor: 2.823

6.  Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.

Authors:  Maha-Hamadien Abdulla; Debbie S Ruelas; Brian Wolff; June Snedecor; Kee-Chong Lim; Fengyun Xu; Adam R Renslo; Janice Williams; James H McKerrow; Conor R Caffrey
Journal:  PLoS Negl Trop Dis       Date:  2009-07-14

7.  Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif.

Authors:  Nina Klee; Pui Ee Wong; Beatriz Baragaña; Farah El Mazouni; Margaret A Phillips; Michael P Barrett; Ian H Gilbert
Journal:  Bioorg Med Chem Lett       Date:  2010-06-17       Impact factor: 2.823

8.  A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427.

Authors:  Melissa L Sykes; Vicky M Avery
Journal:  Parasit Vectors       Date:  2009-11-12       Impact factor: 3.876

9.  Advancing drug innovation for neglected diseases-criteria for lead progression.

Authors:  Solomon Nwaka; Bernadette Ramirez; Reto Brun; Louis Maes; Frank Douglas; Robert Ridley
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

10.  One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.

Authors:  Chidochangu P Mpamhanga; Daniel Spinks; Lindsay B Tulloch; Emma J Shanks; David A Robinson; Iain T Collie; Alan H Fairlamb; Paul G Wyatt; Julie A Frearson; William N Hunter; Ian H Gilbert; Ruth Brenk
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.